X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (323) 323
humans (316) 316
male (307) 307
prostate cancer (306) 306
abiraterone acetate (299) 299
oncology (215) 215
prostatic neoplasms, castration-resistant - drug therapy (170) 170
chemotherapy (162) 162
abiraterone (149) 149
metastasis (147) 147
docetaxel (137) 137
enzalutamide (133) 133
care and treatment (118) 118
prostatic neoplasms, castration-resistant - pathology (110) 110
treatment outcome (110) 110
cancer (109) 109
aged (108) 108
increased survival (103) 103
double-blind (101) 101
androgens (100) 100
prostatic neoplasms - drug therapy (100) 100
urology & nephrology (99) 99
middle aged (97) 97
antineoplastic agents - therapeutic use (96) 96
survival (90) 90
cancer therapies (87) 87
antitumor-activity (79) 79
castration-resistant prostate cancer (79) 79
men (78) 78
pharmacology & pharmacy (74) 74
prednisone (74) 74
research (74) 74
castration (72) 72
phenylthiohydantoin - analogs & derivatives (71) 71
aged, 80 and over (69) 69
neoplasm metastasis (69) 69
drug therapy (68) 68
survival analysis (67) 67
androgen receptor (63) 63
patients (60) 60
mitoxantrone plus prednisone (59) 59
disease-free survival (57) 57
androgen antagonists - therapeutic use (53) 53
antineoplastic combined chemotherapy protocols - therapeutic use (53) 53
mitoxantrone (53) 53
prostatic neoplasms - pathology (53) 53
clinical trials (52) 52
phenylthiohydantoin - therapeutic use (52) 52
prostate (52) 52
plus prednisone (51) 51
taxoids - therapeutic use (51) 51
antineoplastic agents - adverse effects (50) 50
cabazitaxel (49) 49
health aspects (49) 49
therapy (49) 49
metastases (48) 48
review (46) 46
cyp17 (45) 45
antineoplastic combined chemotherapy protocols - adverse effects (44) 44
disease progression (43) 43
metastatic castration-resistant prostate cancer (43) 43
sipuleucel-t (43) 43
analysis (42) 42
trial (42) 42
prostatic neoplasms, castration-resistant - mortality (41) 41
urology (41) 41
androgen-deprivation therapy (39) 39
development and progression (39) 39
orchiectomy (39) 39
abiraterone acetate - adverse effects (38) 38
i clinical-trial (38) 38
open-label (38) 38
prostate-specific antigen - blood (38) 38
quality of life (37) 37
abiraterone acetate - administration & dosage (35) 35
immunotherapy (35) 35
phenylthiohydantoin - adverse effects (35) 35
testosterone (35) 35
prognosis (34) 34
phase-ii (33) 33
prostatic neoplasms, castration-resistant - blood (33) 33
quality-of-life (33) 33
taxoids - administration & dosage (33) 33
androstenes (32) 32
animals (32) 32
antineoplastic agents - administration & dosage (32) 32
placebo-controlled phase-3 (32) 32
risk factors (32) 32
usage (32) 32
antiandrogen (31) 31
antineoplastic agents, hormonal - therapeutic use (31) 31
clinical trials as topic (31) 31
retrospective studies (31) 31
antineoplastic agents, hormonal - adverse effects (30) 30
bone neoplasms - secondary (30) 30
prednisone - administration & dosage (30) 30
abiraterone acetate - therapeutic use (29) 29
adult (29) 29
androgen deprivation therapy (29) 29
phase-iii trial (29) 29
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 338 - 351
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2017, Volume 377, Issue 4, pp. 352 - 360
Journal Article
European Urology, ISSN 0302-2838, 2017, Volume 72, Issue 1, pp. 10 - 13
Abstract In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naïve metastatic... 
Urology | Androgen signaling–directed therapy | Metastatic castration-resistant prostate cancer | Chemotherapy-naïve | Sequencing | Abiraterone acetate | PLACEBO-CONTROLLED PHASE-3 | SURVIVAL ANALYSIS | Chemotherapy-naive | DOCETAXEL | CHEMOTHERAPY | prostate cancer | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Metastatic castration-resistant | Androgen signaling-directed therapy | ENZALUTAMIDE | Phenylthiohydantoin - adverse effects | Phenylthiohydantoin - therapeutic use | Humans | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Drug Resistance, Neoplasm | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Clinical Trials, Phase III as Topic | Neoplasm Metastasis | Multicenter Studies as Topic | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Kallikreins - blood | Retrospective Studies | Prednisone - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Steroid Synthesis Inhibitors - therapeutic use | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Phenylthiohydantoin - analogs & derivatives | Prostate-Specific Antigen - blood | Randomized Controlled Trials as Topic | Disease-Free Survival | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Prostatic Neoplasms, Castration-Resistant - mortality | Prednisone - therapeutic use | Medical research | Medical colleges | Care and treatment | Corticosteroids | Patient outcomes | Censorship | Prednisone | Metastasis | Acetates | Chemotherapy | Medicine, Experimental | Prostate cancer | Cancer | Steroids
Journal Article
European Urology, ISSN 0302-2838, 2015, Volume 68, Issue 4, pp. 570 - 577
Abstract Background Metastatic castration-resistant prostate cancer (mCRPC) often involves bone, and bone-targeted therapy (BTT) has become part of the overall... 
Urology | Bone-targeted therapy | Metastatic castration-resistant prostate cancer | Chemotherapy-naïve | Abiraterone acetate | SURVIVAL | PLACEBO | Chemotherapy-naive | PHASE-3 | SKELETAL COMPLICATIONS | ANDROGEN-DEPRIVATION THERAPY | ZOLEDRONIC ACID | PREDNISONE | RECOMMENDATIONS | MEN | UROLOGY & NEPHROLOGY | QUALITY-OF-LIFE | Bone Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Clinical Trials, Phase III as Topic | Multicenter Studies as Topic | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Retrospective Studies | Bone Neoplasms - drug therapy | Odds Ratio | Bone Density Conservation Agents - adverse effects | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Steroid Synthesis Inhibitors - therapeutic use | Bone Density Conservation Agents - therapeutic use | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Randomized Controlled Trials as Topic | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Bisphosphonate-Associated Osteonecrosis of the Jaw - etiology | Prednisone - therapeutic use | Cancer patients | Care and treatment | Chemotherapy | Oncology, Experimental | Analysis | Research | Metastasis | Prostate cancer | Acetates | Cancer
Journal Article
The Oncologist, ISSN 1083-7159, 05/2017, Volume 22, Issue 5, pp. 503 - e43
Journal Article
The Journal of Clinical Pharmacology, ISSN 0091-2700, 12/2015, Volume 55, Issue 12, pp. 1406 - 1414
Journal Article
European Urology, ISSN 0302-2838, 2014, Volume 67, Issue 3, pp. 441 - 447
Abstract Background Although abiraterone acetate (abiraterone) has proven efficacy in two randomised phase 3 trials in metastatic castration-resistant prostate... 
Urology | Castration-resistant prostate cancer | Prostate cancer | Abiraterone acetate | ECOG | Performance status | PREDNISONE | MITOXANTRONE | UROLOGY & NEPHROLOGY | INCREASED SURVIVAL | CHEMOTHERAPY | Multivariate Analysis | Cytochrome P-450 Enzyme Inhibitors - therapeutic use | Humans | Middle Aged | Cytochrome P-450 Enzyme Inhibitors - adverse effects | Male | Prostatic Neoplasms, Castration-Resistant - pathology | Antineoplastic Agents, Hormonal - adverse effects | Neoplasm Metastasis | Time Factors | Antineoplastic Agents, Hormonal - therapeutic use | Aged, 80 and over | Kallikreins - blood | Retrospective Studies | Prostatic Neoplasms, Castration-Resistant - blood | Steroid Synthesis Inhibitors - adverse effects | Risk Factors | Abiraterone Acetate - adverse effects | Kaplan-Meier Estimate | Proportional Hazards Models | Steroid Synthesis Inhibitors - therapeutic use | Logistic Models | Treatment Outcome | Abiraterone Acetate - therapeutic use | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostate-Specific Antigen - blood | Canada | Neoplasms, Hormone-Dependent - blood | Neoplasms, Hormone-Dependent - pathology | Aged | Prostatic Neoplasms, Castration-Resistant - mortality | Neoplasms, Hormone-Dependent - drug therapy | Health Status | Care and treatment | Cancer patients | Metastasis | Acetates
Journal Article
European Urology, ISSN 0302-2838, 2016, Volume 70, Issue 5, pp. 718 - 721
Abstract Coadministration of docetaxel and abiraterone acetate plus prednisone (AA + P) may benefit patients with metastatic castration-resistant prostate... 
Urology | Metastatic castration-resistant prostate cancer | Toxicity | Abiraterone acetate | Combination | Androgen receptor | Docetaxel | Safety | Drug-drug interaction | Pharmacokinetics | prostate cancer | UROLOGY & NEPHROLOGY | Metastatic castration-resistant | Humans | Middle Aged | Male | Antineoplastic Agents - administration & dosage | Drug Monitoring - methods | Prostatic Neoplasms, Castration-Resistant - pathology | Dose-Response Relationship, Drug | Abiraterone Acetate - administration & dosage | Neoplasm Metastasis | Antineoplastic Agents - adverse effects | Antineoplastic Agents - pharmacokinetics | Abiraterone Acetate - pharmacokinetics | Taxoids - adverse effects | Prednisone - administration & dosage | Prednisone - adverse effects | Prostatic Neoplasms, Castration-Resistant - blood | Abiraterone Acetate - adverse effects | Antineoplastic Combined Chemotherapy Protocols | Treatment Outcome | Prostatic Neoplasms, Castration-Resistant - drug therapy | Disease Progression | Prostate-Specific Antigen - blood | Taxoids - pharmacokinetics | Disease-Free Survival | Taxoids - administration & dosage | Prednisone - pharmacokinetics | Aged | Neoplasm Staging | Medical research | Care and treatment | Chemotherapy | Corticosteroids | Medicine, Experimental | Prednisone | Metastasis | Prostate cancer | Acetates | Cancer | Steroids
Journal Article
Journal Article
Drugs, ISSN 0012-6667, 9/2017, Volume 77, Issue 14, pp. 1565 - 1576
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 10/2017, Volume 80, Issue 4, pp. 723 - 728
Journal Article